GlassScriptPhysician profile
Jefrey D Lieberman
NPI 1366525057
$246,992.53
in general payments reported to CMS, 2019-2025
32 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $24K · 2021: $25K · 2022: $27K · 2023: $22K · 2024: $22K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $5,725 · Consulting Fee: $4,944 · Travel and Lodging: $3,875 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,406.00 |
| Food and Beverage | $5,724.60 |
| Consulting Fee | $4,944.00 |
| Travel and Lodging | $3,874.57 |
| Education | $119.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $148,761.01 | 2019-2025 | |
| Genzyme Corporation | $40,595.75 | 2019-2025 | |
| Amgen INC. | $32,818.14 | 2019-2025 | Enbrel, Otezla, Uplizna |
| Novartis Pharmaceuticals Corporation | $15,403.99 | 2019-2025 | |
| Sobi, INC | $2,784.73 | 2025 | |
| Janssen Biotech, INC. | $2,625.44 | 2021-2025 | Tremfya |
| Ucb, INC. | $1,820.74 | 2020-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,113.00 | 2019 | |
| Glaxosmithkline, LLC. | $283.08 | 2019-2025 | Benlysta |
| Sanofi-Aventis U.S. LLC | $159.98 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $123.35 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $99.30 | 2022-2025 | Saphnelo |
| Horizon Therapeutics Plc | $75.61 | 2020-2021 | |
| Radius Health, INC. | $57.16 | 2025 | Tymlos |
| Pfizer INC. | $52.21 | 2019-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44.69 | 2021-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.82 | 2023 | |
| Ani Pharmaceuticals, INC. | $24.41 | 2024 | Purified Cortrophin Gel |
| Sandoz INC. | $22.94 | 2023 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $22.90 | 2025 | Opsumit, Uptravi |
| Genentech USA, INC. | $20.88 | 2025 | Gazyva |
| Celltrion USA INC. | $19.98 | 2023 | Yuflyma |
| Alexion Pharmaceuticals, INC. | $18.98 | 2025 | Strensiq |
| Sanofi Pasteur INC. | $17.44 | 2023 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefrey Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.